Navigation Links
Are siRNA Pools Smart?

Screening with small interfering RNAs (siRNAs) is an important method for identifying genes involved in biological pathways. This article analyzes the effectiveness of two strategies--transfection of individual siRNAs and transfection of pools of siRNAs--for large-scale screening experiments. The increased effectiveness of testing at least two distinct, algorithm-derived siRNAs to the same target results in decreased use of resources required to screen false positive targets, and more importantly, minimizes the risk of missing valid targets.

In initial RNA interference studies, many researchers opted to combine multiple small interfering RNAs (siRNAs) that targeted distinct regions of the same gene to facilitate degradation of the target mRNA. The desire to mix siRNAs arose primarily from the finding that less than 50% of random-designed siRNAs significantly reduced target gene expression. These experiments showed that combinations of siRNAs did not appear to function synergistically to affect target gene expression, and on occasion less active siRNAs interfered with the activities of the higher efficacy siRNAs. Nevertheless, the pooling strategy increased the chances of reducing target gene expression of random-designed siRNAs.

The realization that potent siRNAs share sequence characteristics has led to siRNA design algorithms that significantly improve the percentage of effective siRNA sequences. For instance, the Cenix siRNA design algorithm--upon which Ambion's Silencer Pre-designed siRNAs are based--has a success rate of >80%, with the majority of the siRNAs providing >85% reduction in target gene expression (Figure 1). Given the success rate of individual algorithm-designed siRNAs, the benefits of siRNA pooling have decreased (Figure 2). Furthermore, the recent observations of off-target effects by siRNAs [1] suggest that combining multiple siRNAs might actually increase the chances that genes other than the target are being affected.

Figure 1. Efficacy of Silencer Pre-designed siRNAs. More than 1100 siRNAs targeting nearly 400 endogenously expressed human genes were tested for target mRNA reduction. More than 82% of the siRNAs reduced target gene expression by at least 70% and more than 61% reduced target gene expression by at least 85%. All siRNA designs were based on an algorithm developed by Cenix BioScience.

Figure 2. Target mRNA Reduction by Single siRNAs and siRNA Pools. Cells transfected with three individual Silencer Pre-designed siRNAs (30 nM) or a pool of all three siRNAs (10 nM each) were monitored for target mRNA reduction by real-time RT-PCR 48 h post-transfection. Relative target mRNA expression was taken as a percentage of mRNA expressed in cells transfected with Silencer Negative Control #1 siRNA (Ambion). All real-time RT-PCR data were normalized with 18S rRNA real-time RT-PCR.

Comparing siRNA Pools and Single siRNAs: Experimental Design and Results

Quantitative, phenotypic assays were used to determine how well single siRNAs performed relative to siRNA pools. siRNAs targeting 59 kinases, along with positive and negative control siRNAs, were studied. Cell populations were transfected with three single siRNAs (siRNA #1, siRNA #2, or siRNA #3), all targeting the same gene, or a pool of the three siRNAs (siRNA #1 + siRNA #2 + siRNA #3). In the experiments described below, cell number was monitored three days post-transfection (Figure 3), or apoptosis was induced using etoposide one day after transfection, and caspase 3 activity was assayed three days post-transfection (Figure 4). All transfected cells were assayed on the same day using master mixes of dyes and substrates to minimize experimental variability in the studies.

[click here to enlarge]

Figure 3. Cell Proliferation--Single siRNAs vs. siRNA Pools. (A) Expression levels of 59 kinases were reduced in HeLa cells by transfection in 96 well plates of three individual kinase-specific siRNAs or a pool of the three siRNAs. All samples were performed in triplicate. To each well containing siPORT NeoFX Transfection Agent and either one of three siRNAs (30 nM) or the three pooled siRNAs (10 nM each), 8x103 HeLa cells were added in a process termed reverse transfection [2]. Three days post-transfection, the cells were assayed using alamarBlue (AccuMed International). The mean standard deviation is presented. The bars in the graph represent the average alamarBlue result for each siRNA or siRNA pool relative to a negative control (Silencer Negative Control #1 siRNA; Ambion) transfected sample. (B) Representative results from specific genes are presented to exemplify the types of agreement and disagreement that occurred between expression results using the various siRNA combinations. Zero on the y axis is set to 2 standard deviations below the average signal from the negative control transfected samples. Bars that fall below zero are significantly different than the negative control and thus represent hits in our assay.

[click here to enlarge]

Figure 4. Caspase 3 Activation--Single siRNAs vs. siRNA Pools. (A) The expression levels of 59 kinases were reduced in HeLa cells by transfection of three single kinase-specific siRNAs or a pool of the siRNAs in 96 well plates. All samples were performed in triplicate. One day post-transfection, the cells were treated with etoposide to activate the apoptosis pathway. Three days post-transfection, the cells were counted and lysed. The caspase 3 activity in the lysates was assayed and normalized by cell number. The mean standard deviation of the three replicates is presented, where zero on the y axis is set to 2 standard deviations below the average signal from the negative control transfected samples. So bars that fall below zero are significantly different than the negative control and thus represents hits in our assay. The bars in the graph represent the mean caspase 3 activity relative to a negative control (Silencer Negative Control #1 siRNA; Ambion) transfected sample. (B) Representative results from specific genes illustrate the types of agreement and disagreement that occurred between the various siRNAs.

Cell Proliferation Results
Cell number was measured using an alamarBlue (AccuMed International) microplate-based assay. These results were confirmed by high-throughput microscopy. As shown in Figure 3A, siRNAs targeting the various kinases differentially affected cell number relative to negative control transfected samples. Different siRNAs targeting the same gene typically had similar effects on cell proliferation; however, it was common for one of the three single siRNAs to behave differently from the other two siRNAs. Similarly, siRNA pools often failed to display a phenotype consistent with the majority of the siRNAs that were individually transfected (Figure 3B).

Apoptosis Assay Results
During screens for kinases that influence apoptosis, both cell number and caspase 3 activity were measured following siRNA transfection and etoposide treatment. Assaying for cell number was necessary because some of the transfected siRNAs differentially altered cell growth or survival. Normalization of the caspase 3 activity data by cell number allowed us to express data as caspase 3 activity per cell. As expected, reducing expression of several kinases inhibited activation of caspase 3 by etoposide, suggesting that these kinases play a role in apoptosis (Figure 4). Consistent with the cell proliferation results, the single siRNAs for each gene had similar, though non-identical effects, on caspase 3 activity. Also consistent with the cell proliferation results, the siRNA pools only partially overlapped the results of the single siRNAs (Figure 5). Examples of single and pooled siRNA results are shown in Figure 4B.

Figure 5. Overall Performance of Single siRNAs and siRNA Pools. Using the definition of a hit as a gene for which two single siRNAs produce a phenotype that is significantly different than samples transfected with a negative control siRNA, the performance of each of the single siRNAs (siRNA #1, #2, or #3) as well as the siRNA pool of the three siRNAs was compared. The combined results of screening with two (#1+#2, #1+#3, and #2+#3) or three (#1+#2+#3) individual siRNAs illustrates the higher accuracy of this strategy. Accurate predictions of hits and inaccurate predictions of hits are shown in green and orange, respectively. False negatives are shown in grey.

Single siRNAs vs. siRNA Pools: Results

To minimize experimental variability, the data comparing the effects of single and pooled siRNAs on proliferation and caspase 3 activation were generated with the same cell line and substrates at the same time. The results of the screens were used to determine the effectiveness of transfecting a series of three single siRNAs versus transfecting a pool of the three siRNAs for identifying gene "hits." The definition of a hit in our screen was a gene for which two single siRNAs generated a phenotype that was statistically different from the negative control (Silencer Negative Control #1 siRNA, Ambion) transfected samples in the screening experiment.

False Positives . For both proliferation and caspase 3 assays, less than 60% of the hits predicted by the pooled siRNA results could be validated by the single siRNAs (False Positives, Figure 5).

False Negatives. While the analysis of false positives wastes time and resources, of greater concern were the genes that failed to register as hits when the gene target did indeed participate in the pathway being analyzed. These occurrences, referred to as false negatives, were especially prevalent for the siRNA pools: Results from pooled siRNAs suggested that the gene was not involved in the apoptosis pathway, whereas results from two or more individual siRNAs to the same target suggested the gene was important for activation of the apoptosis pathway. In both screens, the pooled siRNA experiments had a 50% false negative rate, indicating that screening with siRNA pools can result in lost opportunities for target gene identification.

Use of more than one individual siRNA. Though less problematic than experiments using siRNA pools, studies involving only a single gene-specific siRNA were prone to the relatively high rates of false positives and false negatives described above. The use of two, and preferably three, distinct siRNAs per gene significantly decreased the false negative rates of screening, making it possible to identify a more complete complement of interesting genes within the collection being analyzed (Figure 5).

Phenotype vs. siRNA Efficacy

One possible explanation for the discrepancy between single siRNAs and pooled siRNAs is that the levels of target gene expression following transfection were different in each case. To address this, we measured cell number and mRNA knockdown in cells transfected with single and pooled siRNAs targeting nine different genes. As shown in Figure 6, the average correlation between cellular phenotype and mRNA knockdown for each of the different genes was low, indicating that the variability in phenotypes induced by different siRNAs was unlikely to have been caused by siRNA efficacy.

[click here to enlarge]

Figure 6. Phenotype vs. mRNA Knockdown in Transfected Cells. HeLa cells were transfected with three different single siRNAs as well as an siRNA pool targeting each of the nine genes shown on the x-axis. Three days post-transfection, the wells were assayed for cell number (A) using alamarBlue (AccuMed International). The RNA in the cells was isolated and assayed for target mRNA expression by real-time RT-PCR (B). The alamarBlue and the target mRNA quantification are presented as percentages of cells transfected with with Silencer Negative Control #1 siRNA (Ambion).


Similar comparisons of single siRNAs versus pooled siRNAs were carried out using nine different phenotypic assays including protein activation, cell morphology, and cytoskeleton formation. Our results demonstrated that experiments using pooled siRNAs consistently yielded false positive rates of >50% and false negative rates >40%. Testing a single siRNA per target had slightly lower, though no less onerous, rates of false positives and false negatives. The phenotypic differences between single siRNAs and pooled siRNAs targeting the same gene likely reflect the variability in off-target effects of siRNAs. To overcome this, we found it extremely important to use several individual siRNAs per target gene in individual transfections to confirm that a phenotype was specific to the reduction of gene expression and not due to off-target effects of a single siRNA or an siRNA pool.

Scientific Contributors
David Brown, Mike Byrom, Joe Krebs, Kevin Kelnar, Rich Jarvis, Amanda Campbell, Lance Ford Ambion, Inc.

back to top

Ordering Information Cat# Product Name Size 16704 Silencer Pre-designed siRNA, standard purity, annealed 20 nmol 51320 Silencer Validated siRNA 5 nmol


Page: All 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Custom and library siRNA for efficient gene silencing
2. Custom and library siRNA for efficient gene silencing
3. Cancer siRNA Oligo Set Version 1.0
4. Library siRNA
5. Custom siRNA Oligo Synthesis Service
6. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
7. Quantification of siRNA Silencing Efficiency Using the LightCycler System
8. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
9. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
10. siRNA transfection optimization with the Agilent 2100 bioanalyzer
11. siRNA Design Guidelines
Post Your Comments:

(Date:3/24/2017)... and ROCKVILLE, Md. , March ... of Maxwell Biotech Venture Fund (MBVF), today announced positive ... added to the standard drug therapy regimen in patients ... small molecule drug discovered by scientists at Sequella, Inc. ... Institutes of Health. A total of ...
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or ... China , today announced that its board of ... date of the plan from March 27, 2017 to March 27, ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/24/2017)... 2017   Sienna Biopharmaceuticals, Inc. , a privately ... that Richard Peterson will join the company ... Peterson, who brings more than two decades of global ... is retiring at the end of April but will ... joins Sienna from Novan, Inc., where he served as ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, ... viscous and elastic characteristics when deformed, which is identical to how the human ... absorb compressive forces and return to its natural state along a hysteresis curve, ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
Breaking Biology News(10 mins):